SCHEMBL4282964

SCHEMBL4282964

CC(=O)Nc1ccc(NC(=O)c2cc(-c3cccs3)on2)cc1

nearest known ligand 0.81

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.81
POLB P06746 3/20 0.79
MEN1 O00255 8/20 0.77
KMT2A Q03164 8/20 0.77
MAPT P10636 9/20 0.76
TP53 P04637 3/20 0.76
THRB P10828 2/20 0.76
ALDH1A1 P00352 6/20 0.74
LMNA P02545 3/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
HPGD P15428 2/20 0.69
HSD17B10 Q99714 2/20 0.69
NPSR1 Q6W5P4 1/20 0.69
RAB9A P51151 3/20 0.67
TDP1 Q9NUW8 1/20 0.67
HTT P42858 1/20 0.66
NPC1 O15118 2/20 0.63
TSHR P16473 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4291437 0.93 MEN1 (0.80) KDM4EPOLBMEN1KMT2AMAPT
SCHEMBL17318590 0.90 MEN1 (0.80) KDM4EPOLBMEN1KMT2AMAPT
SCHEMBL4282643 0.88 POLB (0.81) KDM4EPOLBMEN1KMT2AMAPT
SCHEMBL4284405 0.87 RAB9A (0.73) KDM4EPOLBMEN1KMT2AMAPT
SCHEMBL4286750 0.87 POLB (0.79) KDM4EPOLBMEN1KMT2AMAPT
SCHEMBL17318501 0.86 KDM4E (0.76) KDM4EPOLBMEN1KMT2AMAPT
SCHEMBL17318499 0.86 MAPT (1.00) KDM4EPOLBMEN1KMT2AMAPT
SCHEMBL17318502 0.84 KDM4E (1.00) KDM4EPOLBMEN1KMT2AMAPT
SCHEMBL17318520 0.84 MEN1 (1.00) KDM4EPOLBMEN1KMT2AMAPT
SCHEMBL17318610 0.82 MAPT (1.00) KDM4EPOLBMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404304-B1 Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same SIERRA SCIENCES, LLC (US) 2025-09-02 US disclosed
US-20250179122-A1 Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same SIERRA SCIENCES, LLC 2025-06-05 US disclosed
US-20090143451-A1 COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME SIERRA SCIENCES INC. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179122-A1 Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same TERT, RNGTT, TERF2 KDM4E 1668/4885POLB 29/4885MEN1 3080/4885
US-12404304-B1 Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same TERT, TELO2, POT1 KDM4E 541/4885POLB 284/4885MEN1 4306/4885
US-20090143451-A1 COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME TERT, TERF2, RNMT KDM4E 1910/4885POLB 24/4885MEN1 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.